考比司他增效埃替拉韦与达芦那韦在HIV感染者中的药代动力学相互作用
该研究评估考比司他增效埃替拉韦与每日一次800 mg达芦那韦同服时的药物相互作用。结果显示,联合用药组与单独用药组的埃替拉韦和达芦那韦谷浓度(C24)相似,考比司他浓度也相当,提示无显著相互作用。
要点
- 埃替拉韦与达芦那韦同服时,两者C24浓度与单独用药时相似。
- 考比司他C24在联合用药组与单用组相当,无显著差异。
- 临床可考虑将考比司他增效埃替拉韦与800 mg达芦那韦每日一次联合使用。
核心结论
- 考比司他增效埃替拉韦与800 mg达芦那韦每日一次同服时,埃替拉韦和达芦那韦的C24浓度与分开给药时相似,未发现显著相互作用。
研究设计与样本
- 研究纳入三组未筛选的志愿者:A组服用埃替拉韦/考比司他/恩曲他滨/替诺福韦DF复方片加800 mg达芦那韦;B组仅服用复方片;C组服用考比司他增效达芦那韦加两种核苷(酸)类似物。
- 共从A、B、C三组分别24、32、32例患者中获得170份样本,用验证过的LC-MS/MS法测定埃替拉韦、考比司他和达芦那韦的C24浓度。
主要发现
- A组埃替拉韦C24为233.67 ng/mL,B组为250.39 ng/mL,差异无统计学意义(P=0.406)。
- A组达芦那韦C24为1293.54 ng/mL,C组为1319.34 ng/mL,差异无统计学意义(P=0.908)。
- A组考比司他C24为20.2 ng/mL,B组为20.9 ng/mL,C组为27.7 ng/mL,三组间差异无统计学意义(P=0.059)。
临床怎么用
- 对于HIV感染者,可考虑将考比司他增效埃替拉韦复方片与800 mg达芦那韦每日一次同时服用,无需调整剂量。
局限性
- 研究为小样本、非随机分组,可能影响结果的普遍性。
- 仅测定谷浓度(C24),未评估其他药代动力学参数或临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate if there are significant drug-drug interactions between cobicistat-boosted elvitegravir and 800 mg darunavir once daily taken simultaneously, as has been suggested previously. METHODS: The study population consisted of three groups of unselected volunteers taking a regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (150, 150, 200 and 300 mg, respectively) co-formulated in a single tablet plus 800 mg darunavir (group A); only co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (group B); and cobicistat-boosted darunavir (800 mg darunavir + 150 mg cobicistat) plus two nucleos(t)ide analogues (group C). Elvitegravir, cobicistat and darunavir concentrations at the end of the dosing interval ( C 24 ) were quantified using a validated LC with tandem MS method. RESULTS: A total of 170 samples were obtained from 24, 32 and 32 patients in groups A, B and C, respectively. In group A, the elvitegravir C 24 were similar to those in group B (233.67 versus 250.39 ng/mL) ( P = 0.406) and the darunavir C 24 were similar to those in group C (1293.54 versus 1319.34 ng/mL) ( P = 0.908). The cobicistat C 24 were comparable in groups A and B (20.2 versus 20.9 ng/mL) and slightly higher in group C (27.7 ng/mL) ( P = 0.059). CONCLUSIONS: The results provide evidence of similar elvitegravir and darunavir C 24 concentrations when these drugs are co-administered as co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate plus 800 mg darunavir or dosed separately.
引用
- Gutierrez-Valencia A, Benmarzouk-Hidalgo OJ, Llaves S, et al. Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients. J Antimicrob Chemother. 2017. PMID: 27999051. doi:10.1093/jac/dkw487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。